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We thank Drs. Zheng and Wang for their comments (1) regarding fibroblast growth factor 23 (FGF23) compared with serum phosphorus concentration for prediction of mortality in the African AmericanDiabetes Heart Study (AA-DHS). Mildly elevated mean serum phosphorus concentrations and calcium-phosphorus products, well within their normal ranges, are cardiovascular disease risk factors and predict death in populations without chronic kidney disease (CKD) (2, 3 ), permitting analyses with low likelihood of confounding from CKD. Although Zheng and Wang (1) state that "serum phosphorus is the main stimulus for FGF23 secretion," regulation of FGF23 is a complex and incompletely understood process, particularly in the earliest stages of CKD (5). With the exception of patients with end-stage kidney disease, serum phosphorus concentrations have not shown immediate and consistent effects on the secretion of FGF23 (5).
We performed additional analyses to address their questions on the effects of serum phosphorus and the calciumphosphorus product on mortality in the AA-DHS (4 was weakly correlated with serum phosphorus and calcium-phosphorus product in these participants (r = 0.17 and 0.15, respectively; both P , 0.01). Adjusting for age, sex, and African ancestry proportion in a multivariate analysis, as was performed for FGF23 (see Table 3 in Chan et al. [4] , models 1 and 2), serum phosphorus and calcium-phosphorus product were not significant predictors of mortality in the AA-DHS. We observed hazard ratios for mortality of 0.91 (95% CI 0.69, 1.21) and 0.82 (0.62, 1.10) for serum phosphorus and calcium-phosphorus product, respectively (P . 0.15 in both).
In the fully adjusted models, the hazard ratios were 0.80 (95% CI 0.59, 1.09) for serum phosphorus and 0.74 (0.54, 1.02) for calcium-phosphorus product; P values were 0.16 and 0.06, respectively. A total of 508 AA-DHS participants had both FGF23 and serum phosphorus measurements, and 54 deaths were recorded during a median 6.6-year followup. In contrast, the Cholesterol And Recurrent Events (CARE) study that assessed serum phosphorus and mortality in individuals with prior myocardial infarctions had better power (2); CARE included 4,127 individuals (136 African American) with 375 deaths during a 5-year follow-up.
In conclusion, plasma FGF23 significantly predicted mortality in the AA-DHS, whereas serum phosphorus and the calciumphosphorus product did not. These results support use of FGF23 to predict mortality in African Americans with type 2 diabetes who lack nephropathy.
